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The Early Breast Cancer Trials Collaborative Group
(EBCTCG) is a global organization of trialists that has
conducted randomized clinical trials of therapies in early
breast cancer. This organization, with its Data Management
and Analysis Center in Oxford, England, has conducted meta-
analyses of a variety of therapies, producing information that
is not available from individual trials. This process has
become known as the Oxford Overview.
The first organizational meeting of the trialists was held in
1984 [1]. Over the past two decades, the Oxford Overview
has produced a number of publications that have increased
our understanding of the impact that various therapeutic
approaches have on overall survival and breast cancer
specific events, in addition to potential adverse events.
Recent updates of the therapeutic modalities have included
polychemotherapy, tamoxifen and ovarian oblation/suppres-
sion [2], and radiation therapy [3]. The Oxford Overview
process aims to include all of the randomized evidence, thus
providing insights that would not be available from examining
individual trials. Of particular importance to this process is the
requirement of the Oxford Overview for long-term follow up,
which has provided information on outcomes out to 15 years
that it would simply not be available from individual trials.
The EBCTCG has held main meetings every 5 years. The
most recent meeting was held in September 2006. Areas of
focus included updated information on polychemotherapy,
anthracyclines, tamoxifen and ovarian ablation/suppression.
New meta-analyses were considered in postmastectomy
radiation therapy, aromatase inhibitors, taxanes and high-
dose chemotherapy. An overview on use of luteinizing-hor-
mone releasing hormone analogues for ovarian function
suppression was recently published [4]. In addition, material
from the ongoing analyses was presented by Richard Peto at
the 2006 San Antonio Breast Cancer Symposium and the
2007 American Society of Clinical Oncology Annual Meeting.
It is anticipated that main publications of these analyses will
occur over the next 2 years as the data are finalized and
analysis completed.
The question arises as to whether the Oxford Overview
process will diminish in value or become obsolete as the
sample size of patients enrolled in clinical trials continues to
increase. The number of patients enrolled in the recent
generation of trials has been in the 4,000 to 7,000 range,
which is many times greater than was the case when the
EBCTCG was formed several decades ago. It is clear that
the Oxford Overview process remains highly relevant despite
the changing character of the clinical trials. The Oxford
Overview provides the mechanism for gaining knowledge
relating to end-points such as survival and adverse events
that is not possible with even a large individual trial. It is
anticipated that this will be clearly seen in the aromatase
inhibitor overview, which is in the final stages of analysis and
includes some very large clinical trials such as ATAC
(Arimidex, Tamoxifen Alone or Combination) and BIG (Breast
International Group) 1-98.
Additional advantages of the overview process include the
collaboration and communication that are inherent in the
conduct of meta-analyses. The Oxford Overview also has the
potential to expand analysis into areas such as biomarkers.
Such an expansion would greatly enhance the value of the
overview process, but it would require even greater sharing of
data than currently exists. A general rule is that the clinical
trials groups do not submit data for the Oxford Overview until
publication of results regarding protocol-specified end-points
has been accomplished. Involvement in the Oxford Overview
should have the impact of expediting publications by the
different trial organizations. It is clear that the success of the
Oxford Overview is a function of the commitment by the
trialists because it is their data that are being analyzed.
Because commitment to this process requires expenditure of
effort, which in turn requires financial support, there is an
element of altruism that is not insignificant.
In summary, the Oxford Overview will continue to be
successful to the extent that it provides information of value
to investigators and ultimately to patients in a timely manner.
Publications of ongoing analyses should provide unequivocal
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evidence over the next several years of the continuing
importance and value of the Oxford Overview.
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